Genesis Healthcare Inc. [NYSE: GEN] stock went on a downward path that fall over -8.42% on Tuesday, amounting to a one-week price decrease of less than -14.30%. The company report on March 23, 2021 that Highly Regarded Turnaround Specialist, Harry Wilson, Appointed CEO of Genesis HealthCare.
Company to build on solid foundation and further strengthen patient care and resident experience.
Genesis Healthcare, Inc. (Genesis, or the Company) (NYSE: GEN), a national post-acute care provider, announced that Harry Wilson has been appointed as the Company’s new Chief Executive Officer (CEO), replacing CEO, Robert (“Bob”) H. Fish. Mr. Wilson will also join the Company’s Board of Directors, replacing James McKeon. The Company also announced that David Harrington has been appointed Executive Chairman, and Mr. Fish will remain a member of the Board.
Over the last 12 months, GEN stock dropped by -42.01%. The average equity rating for GEN stock is currently 3.50, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $74.33 million, with 113.29 million shares outstanding and 63.80 million shares in the current float. Compared to the average trading volume of 7.04M shares, GEN stock reached a trading volume of 5215383 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Genesis Healthcare Inc. [GEN]:
Stifel have made an estimate for Genesis Healthcare Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 29, 2018. While these analysts kept the previous recommendation, RBC Capital Mkts raised their target price from $3 to $3.50. The new note on the price target was released on November 21, 2016, representing the official price target for Genesis Healthcare Inc. stock. Previously, the target price had yet another drop from $5 to $3, while RBC Capital Mkts kept a Outperform rating on GEN stock.
The Average True Range (ATR) for Genesis Healthcare Inc. is set at 0.09, with the Price to Sales ratio for GEN stock in the period of the last 12 months amounting to 0.02. Price to Free Cash Flow for GEN in the course of the last twelve months was 0.29 with Quick ratio for the last quarter at 0.20.
GEN Stock Performance Analysis:
Genesis Healthcare Inc. [GEN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -14.30. With this latest performance, GEN shares dropped by -46.13% in over the last four-week period, additionally sinking by -21.81% over the last 6 months – not to mention a drop of -42.01% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GEN stock in for the last two-week period is set at 36.80, with the RSI for the last a single of trading hit 34.22, and the three-weeks RSI is set at 39.59 for Genesis Healthcare Inc. [GEN]. The present Moving Average for the last 50 days of trading for this stock 0.7338, while it was recorded at 0.5470 for the last single week of trading, and 0.6561 for the last 200 days.
Insight into Genesis Healthcare Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Genesis Healthcare Inc. [GEN] shares currently have an operating margin of -6.91 and a Gross Margin at -2.42. Genesis Healthcare Inc.’s Net Margin is presently recorded at -1.51.
Return on Total Capital for GEN is now -8.93, given the latest momentum, and Return on Invested Capital for the company is -3.45. Additionally, GEN Total Debt to Total Capital is recorded at 127.43, with Total Debt to Total Assets ending up at 93.79.
Reflecting on the efficiency of the workforce at the company, Genesis Healthcare Inc. [GEN] managed to generate an average of -$1,255 per employee. Receivables Turnover for the company is 7.86 with a Total Asset Turnover recorded at a value of 0.86.Genesis Healthcare Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.20 and a Current Ratio set at 0.20.
GEN Stock EPS
With the latest financial reports released by the company, Genesis Healthcare Inc. posted -0.1/share EPS, while the average EPS was predicted by analysts to be reported at -0.11/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 9.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GEN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Genesis Healthcare Inc. go to 10.00%.
Genesis Healthcare Inc. [GEN] Insider Position Details
There are presently around $8 million, or 16.90% of GEN stock, in the hands of institutional investors. The top three institutional holders of GEN stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 3,700,438, which is approximately -3.24% of the company’s market cap and around 0.30% of the total institutional ownership; FIRST WASHINGTON CORP, holding 3,004,969 shares of the stock with an approximate value of $1.5 million in GEN stocks shares; and ACADIAN ASSET MANAGEMENT LLC, currently with $1.32 million in GEN stock with ownership of nearly 26.942% of the company’s market capitalization.
Positions in Genesis Healthcare Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 19 institutional holders increased their position in Genesis Healthcare Inc. [NYSE:GEN] by around 1,024,136 shares. Additionally, 24 investors decreased positions by around 7,374,928 shares, while 19 investors held positions by with 8,346,968 shares. The mentioned changes placed institutional holdings at 16,746,032 shares, according to the latest SEC report filing. GEN stock had 7 new institutional investments in for a total of 211,344 shares, while 13 institutional investors sold positions of 3,382,851 shares during the same period.